PresentationGood afternoon, ladies and gentlemen, and welcome to the continued improvement in PFS with iSCIB1+ in advanced melanoma Phase II update, ESMO IO. [Operator Instructions] I would like to remind all participants that this call is being recorded.Phillip L'HuillierCEO & Director Thank you. Good afternoon. Good morning, everyone. Thank you for joining us today. Today, I'm excited to share with you an update on the SCOPE data. And we're calling this presentation redefining the standard of care of adva ...

Core Insights - Genentech, a member of the Roche Group, announced positive results from the Phase III evERA Breast Cancer study [1] - The study demonstrated that giredestrant in combination with everolimus significantly reduced the risk of disease progression or death [1] Study Results - The combination therapy reduced progression-free survival (PFS) by 44% in the intention-to-treat (ITT) population [1] - In the ESR1-mutated population, the risk of disease progression or death was reduced by 62% compared to standard-of-care endocrine therapy plus everolimus [1]